BDNF reduces the retinal toxicity of verteporfin photodynamic therapy

Daniel M. Paskowitz, George Nune, Douglas Yasumura, Haidong Yang, Robert B. Bhisitkul, Shivani Sharma, Michael T. Matthes, Marco A. Zarbin, Matthew M. LaVail, Jacque L. Duncan

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


PURPOSE. Verteporfin photodynamic therapy (PDT) is the most effective treatment for age-related macular degeneration, using laser activation of a photosensitizing dye to achieve closure of choroidal neovascularization. Although PDT preferentially affects pathologic vessels, it can also cause collateral damage to the overlying retina. In the current study, it was found that the neuroprotective agent brain-derived neurotrophic factor (BDNF) reduces this retinal damage. METHODS. Normal adult rats received intravitreal BDNF in one eye and PBS or no injection in the other eye 2 days before PDT. RESULTS. Control eyes exhibited choroidal hypofluorescence, moderate to severe photoreceptor loss, and depression of local retinal function measured using multifocal ERG in the laser-treated area. BDNF-injected eyes had more surviving photoreceptors and improved multifocal ERG responses 1 week after PDT. BDNF did not diminish the effect of PDT on the choroidal circulation as assessed by fluorescein angiography, and there was no evidence of retinal toxicity due to BDNF treatment. CONCLUSIONS. These results suggest that adjunctive neuroprotective therapy may reduce collateral damage to photoreceptors and improve visual outcome after PDT.

Original languageEnglish (US)
Pages (from-to)4190-4196
Number of pages7
JournalInvestigative Ophthalmology and Visual Science
Issue number11
StatePublished - Nov 2004

All Science Journal Classification (ASJC) codes

  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Ophthalmology


Dive into the research topics of 'BDNF reduces the retinal toxicity of verteporfin photodynamic therapy'. Together they form a unique fingerprint.

Cite this